Cargando…

Efficacy and safety of baricitinib for the treatment of hospitalized adults with COVID-19: a systematic review and meta-analysis

OBJECTIVES: Several clinical trials have evaluated the efficacy and safety of baricitinib in COVID-19 patients. Recently, there have been reports on critical patients, which are different from previous research results. The meta-analysis was performed to investigate the effects of baricitinib in COV...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Jing, Wang, Shufang, Ma, Xin, Wei, Qingqing, Peng, Yujuan, Bai, Ying, Miao, Guobin, Meng, Chang, Liu, Peng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10661565/
https://www.ncbi.nlm.nih.gov/pubmed/37990249
http://dx.doi.org/10.1186/s40001-023-01403-0
_version_ 1785148472036425728
author Sun, Jing
Wang, Shufang
Ma, Xin
Wei, Qingqing
Peng, Yujuan
Bai, Ying
Miao, Guobin
Meng, Chang
Liu, Peng
author_facet Sun, Jing
Wang, Shufang
Ma, Xin
Wei, Qingqing
Peng, Yujuan
Bai, Ying
Miao, Guobin
Meng, Chang
Liu, Peng
author_sort Sun, Jing
collection PubMed
description OBJECTIVES: Several clinical trials have evaluated the efficacy and safety of baricitinib in COVID-19 patients. Recently, there have been reports on critical patients, which are different from previous research results. The meta-analysis was performed to investigate the effects of baricitinib in COVID-19, by pooling data from all clinically randomized controlled trials (RCTs) available to increase power to testify. METHODS: Studies were searched in PubMed, Embase, and Cochrane Library databases on January 31, 2023. We performed a meta-analysis to estimate the efficacy and safety of baricitinib for the treatment of hospitalized adults with COVID-19. This study is registered with INPLASY, number 202310086. RESULTS: A total of 3010 patients were included in our analyses. All included studies were randomized controlled trials or prospective study. There was no difference in 14-day mortality between the two groups [OR 0.23 (95% CI 0.03–1.84), I(2) = 72%, P = 0.17]. In subgroup analyses we found that baricitinib did not seem to improve significantly in 24-day mortality critically ill patients [OR 0.60 (95% CI 0.35–1.02), I(2) = 0%, P = 0.06]. Fortunately, baricitinib have led to faster recovery and shorter hospital stays for COVID-19 patients. There were no difference in infections and infestations, major adverse cardiovascular events, deep vein thrombosis and pulmonary embolism. CONCLUSIONS: Baricitinib did not increase the incidence of adverse reactions. At the same time, we can find that it reduces the mortality of COVID-19 patients, not including the critically ill. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40001-023-01403-0.
format Online
Article
Text
id pubmed-10661565
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-106615652023-11-21 Efficacy and safety of baricitinib for the treatment of hospitalized adults with COVID-19: a systematic review and meta-analysis Sun, Jing Wang, Shufang Ma, Xin Wei, Qingqing Peng, Yujuan Bai, Ying Miao, Guobin Meng, Chang Liu, Peng Eur J Med Res Research OBJECTIVES: Several clinical trials have evaluated the efficacy and safety of baricitinib in COVID-19 patients. Recently, there have been reports on critical patients, which are different from previous research results. The meta-analysis was performed to investigate the effects of baricitinib in COVID-19, by pooling data from all clinically randomized controlled trials (RCTs) available to increase power to testify. METHODS: Studies were searched in PubMed, Embase, and Cochrane Library databases on January 31, 2023. We performed a meta-analysis to estimate the efficacy and safety of baricitinib for the treatment of hospitalized adults with COVID-19. This study is registered with INPLASY, number 202310086. RESULTS: A total of 3010 patients were included in our analyses. All included studies were randomized controlled trials or prospective study. There was no difference in 14-day mortality between the two groups [OR 0.23 (95% CI 0.03–1.84), I(2) = 72%, P = 0.17]. In subgroup analyses we found that baricitinib did not seem to improve significantly in 24-day mortality critically ill patients [OR 0.60 (95% CI 0.35–1.02), I(2) = 0%, P = 0.06]. Fortunately, baricitinib have led to faster recovery and shorter hospital stays for COVID-19 patients. There were no difference in infections and infestations, major adverse cardiovascular events, deep vein thrombosis and pulmonary embolism. CONCLUSIONS: Baricitinib did not increase the incidence of adverse reactions. At the same time, we can find that it reduces the mortality of COVID-19 patients, not including the critically ill. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40001-023-01403-0. BioMed Central 2023-11-21 /pmc/articles/PMC10661565/ /pubmed/37990249 http://dx.doi.org/10.1186/s40001-023-01403-0 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Sun, Jing
Wang, Shufang
Ma, Xin
Wei, Qingqing
Peng, Yujuan
Bai, Ying
Miao, Guobin
Meng, Chang
Liu, Peng
Efficacy and safety of baricitinib for the treatment of hospitalized adults with COVID-19: a systematic review and meta-analysis
title Efficacy and safety of baricitinib for the treatment of hospitalized adults with COVID-19: a systematic review and meta-analysis
title_full Efficacy and safety of baricitinib for the treatment of hospitalized adults with COVID-19: a systematic review and meta-analysis
title_fullStr Efficacy and safety of baricitinib for the treatment of hospitalized adults with COVID-19: a systematic review and meta-analysis
title_full_unstemmed Efficacy and safety of baricitinib for the treatment of hospitalized adults with COVID-19: a systematic review and meta-analysis
title_short Efficacy and safety of baricitinib for the treatment of hospitalized adults with COVID-19: a systematic review and meta-analysis
title_sort efficacy and safety of baricitinib for the treatment of hospitalized adults with covid-19: a systematic review and meta-analysis
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10661565/
https://www.ncbi.nlm.nih.gov/pubmed/37990249
http://dx.doi.org/10.1186/s40001-023-01403-0
work_keys_str_mv AT sunjing efficacyandsafetyofbaricitinibforthetreatmentofhospitalizedadultswithcovid19asystematicreviewandmetaanalysis
AT wangshufang efficacyandsafetyofbaricitinibforthetreatmentofhospitalizedadultswithcovid19asystematicreviewandmetaanalysis
AT maxin efficacyandsafetyofbaricitinibforthetreatmentofhospitalizedadultswithcovid19asystematicreviewandmetaanalysis
AT weiqingqing efficacyandsafetyofbaricitinibforthetreatmentofhospitalizedadultswithcovid19asystematicreviewandmetaanalysis
AT pengyujuan efficacyandsafetyofbaricitinibforthetreatmentofhospitalizedadultswithcovid19asystematicreviewandmetaanalysis
AT baiying efficacyandsafetyofbaricitinibforthetreatmentofhospitalizedadultswithcovid19asystematicreviewandmetaanalysis
AT miaoguobin efficacyandsafetyofbaricitinibforthetreatmentofhospitalizedadultswithcovid19asystematicreviewandmetaanalysis
AT mengchang efficacyandsafetyofbaricitinibforthetreatmentofhospitalizedadultswithcovid19asystematicreviewandmetaanalysis
AT liupeng efficacyandsafetyofbaricitinibforthetreatmentofhospitalizedadultswithcovid19asystematicreviewandmetaanalysis